NCT05447286 - Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study | Biotech Hunter

Enrollment

9

Participants

Timeline

Start Date

May 15, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions

Opioid Use Disorder

Interventions

DRUG

NYX-783

This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.

DRUG

Placebo

This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.

DRUG

Oxycodone

This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.

Trial Locations (2)

06519

Cmhc/Cnru, New Haven

The Yale Stress Center: Yale University, New Haven